Take a trial of UK to unlock this pageFind out more

Medilink Global UK

MEDI 1.63p 0.0  0.0%
01/12/16 30.0k

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
12m Forecast Rolling
PE Ratio (ttm) 5.42
PEG Ratio (ttm)
EPS Growth (ttm) %
Dividend Yield (ttm) %
Valuation (ttm)
Price to Book Value 5.53
Price to Tang. Book
Price to Free Cashflow
Price to Sales
EV to EBITDA
Margin of Safety (beta)
Screens Passed 1 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -43.9%

FINANCIAL BRIEF: For the six months ended 30 June 2016, Medilink-Global UK Ltd revenues increased 34% to L941K. Net income before extraordinary items totaled L362K vs. loss of L132K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other income / (expense) increase from L0K to L334K (income), Administrative Expenses decrease of 11% to L273K (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
A+
A+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for Medilink Global UK
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Daniel Stewart Vadim Alexandre , Allenby Capital Tom McColm ,

Profile Summary

Medilink-Global UK Limited provides third party administrator services via electronic healthcard network that facilitate the administration of medical claims and healthcare data management for insurance companies and corporate clients. The Company's segments include Third party administrator and Software licensing. The Third party administrator (TPA) segment is derived from aggregating Malaysia and Singapore entity. The software licensing segment represent a single entity from Malaysia. It offers its TPA services to facilitate the administration of both the in-patient and out-patient healthcare schemes of corporate organizations and insurance companies. Its claims application software electronic claims clearing system (ECCS) is designed to provide e-eligibility, e-claims adjudication and settlement services for its clients. The Company also offers cross border healthcare solutions. The Company's subsidiaries include Medilink-Global (Asia) Pte Ltd and Medilink-Global (HK) Ltd.

Directors: Kok Fat Shia (CEO) 52, Norman Lott (NEC) 58, Shien Yee Chen (NED) 50,

No. of Employees: 41 No. of Shareholders: n/a


Last Annual December 31st, 2015
Last Interim June 30th, 2016
Incorporated January 7, 2008
Public Since November 18, 2008
Shares in Issue 121,492,004
Free Float 69.2m (57.0%)
Sector Healthcare
Industry Healthcare Providers & Services
Index FTSE Aim All Share , FTSE 350 Lower Yield ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

Address Queensway House Hilgrove Street, KUALA LUMPUR, 59100, Malaysia
Web http://www.medilink-global.com/
Phone +
Contact ()
Auditors Crowe Clark Whitehill LLP

MEDI Share Price Performance MEDIQuote
1.63p
0.0  0.0%
Traded 12:00am · Minimum 15 min delayed · NMS: 30.0k


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.


Should you buy MEDI

Access MEDI Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder